Private provision accounts for half of healthcare goods and services delivered in Africa, filling the gaps left by public services, and strong rates of return make it an attractive investment.
Despite, or maybe because of COVID-19, several large-scale healthcare investments went ahead in 2020 while deals in other sectors were delayed or called off completely. ALN is increasingly involved in digital health and healthtech and draws on expertise from across the firm – including competition, tax and litigation – to provide incisive client advice.
We provide transactional, commercial and contentious advice to large multinational pharmaceutical and healthcare groups, investors, start-ups, universities, research institutions and emerging biotechnology ventures. Our lawyers have an unparalleled perspective of the sector and the insight to advise strategically on the most transformational innovations.
Representative transactions include advising:
In connection with a review of a proposed financial structure for distribution agreements to be entered into in each of Sudan, Ethiopia, Zambia, Zimbabwe, Angola and Mozambique.
in connection with its restructuring process in Rwanda.
An affiliate of TPG, a leading U.S. based private equity firm, in connection with its investment through the Evercare Health Fund, the middle market and growth equity investment platform of TPG, into certain healthcare assets that were held by the Abraaj Growth Markets Health Fund, a private equity vehicle dedicated to building affordable high quality health ecosystems in South Asia and Sub-Saharan Africa by building green field or assembling and growing city-based cornerstone assets.
in connection with their investment in an Algerian law company.
In connection with its tender for a contract from the Ministry of Health of the Government of Kenya for supply, installation and maintenance of medical equipment for Kenya’s forty-two counties.
A holding company owning eight East African companies active in the pharmaceutical industry, and a leading distributor of pharmaceutical products in Kenya, Tanzania, Rwanda and Burundi and the largest manufacturer of parenteral in Uganda, in connection with the exit by AfricInvest and acquisition by the Carlyle Group.
A pharmaceutical formulations manufacturing plant based in Sultanate of Oman, in connection with their setting up of a pharmaceutical manufacturing plant in Kenya in partnership with Nairobi Enterprise.